Clinical trial
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
NCT00171925 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00171925 |
|---|---|
| Title | Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I |
| Official title | Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma Stage I |
| Intervention type | Dietary Supplement, Drug |
| Interventions | Zoledronic acid, Calcium / Vitamin D |
| Enrollment | 143 |
| Start date | Aug 1, 2000 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | Apr 11, 2012 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: